A medicine is only tested on the people who take part in its clinical trials. If those people do not reflect the patients who will eventually use it, doctors may know less about how well it works, or how safe it is, for everyone else. That is why diversity in clinical trials matters, not as a slogan, but as a question of good science and safe medicine. This guide explains what diversity means in clinical research, why it affects the treatments you receive, how representative trials are today, what stands in the way, and what researchers, regulators, and patients can do about it.
Want to help make research more representative?
Clinical trials need participants of every age and background. Search recruiting studies near you and apply in about 5 minutes.
What does diversity mean in clinical trials?
Diversity in clinical trials means that the people taking part reflect the range of people who live with the condition being studied. That includes age, sex, race and ethnicity, but also other factors that can influence how a disease develops or how a treatment works, such as other health conditions, pregnancy, disability, where people live, and their access to care. Inclusion describes the practical side: designing studies, choosing locations, and setting eligibility rules so that these groups can actually take part.
Why diversity in clinical trials matters
People do not always respond to medicines in the same way. Age changes how the body processes drugs, which is why older adults may need different doses. Sex can matter too: in 2013, the FDA lowered the recommended dose of the sleep medicine zolpidem for women after finding that women cleared the drug more slowly, leaving them at higher risk of next-morning drowsiness. Genetics plays a role as well. For example, genetic variants that make the heart medicine clopidogrel less effective are more common in people of East Asian ancestry, something the drug's label now warns about.
When trials include a wide range of participants, researchers can spot these differences before a treatment reaches the public, and doctors can prescribe it with more confidence. When they do not, important questions about safety and effectiveness for some groups may remain unanswered until after approval. Representative trials also matter for trust: people are more likely to accept a treatment when they know it was tested in people like them.

How representative are clinical trials today?
Progress has been uneven. According to FDA data for 2020, about 75% of participants in trials supporting new drug approvals were White, 11% Hispanic, 8% Black, and 6% Asian (STAT, citing FDA data). A 2025 analysis of 341 pivotal trials supporting FDA approvals between 2017 and 2023 found that only 6% enrolled participants in proportions close to the four largest racial and ethnic groups in the US population, and that the share of Black and Hispanic participants decreased over time, while trials conducted in the US enrolled more Black participants than those run largely abroad (Communications Medicine, 2025).
Gaps are not only about race and ethnicity. For decades, women of childbearing potential were largely excluded from early drug trials in the US, a practice the FDA reversed in 1993. Older adults, people with several health conditions, and pregnant women are still often left out, even though they use many of the medicines being tested.
Why do some groups take part less often?
The reasons are usually practical rather than a lack of interest. Many people are simply never told about studies that could suit them. Study sites are often concentrated in large academic centers, so travel time, transport, and time off work can make participation difficult. Strict eligibility criteria can exclude older adults and people with other health conditions. Materials may not be available in a person's first language, and some people worry about costs or are unsure what taking part involves.
Mistrust also plays a role, and it has roots in real events. Between 1932 and 1972, the US Public Health Service study in Tuskegee, Alabama, withheld treatment for syphilis from Black men without their informed consent. More recently, members of the Havasupai Tribe in Arizona gave blood samples for diabetes research in the early 1990s and later learned the samples had been used for other studies they had not agreed to. The tribe sued, and the case was settled in 2010, with the samples returned (PLOS). Experiences like these are one reason modern research places so much emphasis on informed consent and independent ethical oversight.
When gaps in research affect patients
The COVID-19 pandemic offered a clear example. Pregnant women were at higher risk of severe illness, yet a review of COVID-19 vaccine trials found that 97.8% of the 90 trials analyzed excluded pregnant women (PubMed). As a result, early guidance for pregnant women had to rely on limited data, and evidence on vaccine safety in pregnancy came later, from studies after the vaccines were already in use.
Alzheimer's disease is another. According to the Alzheimer's Association, older Black Americans are about twice as likely, and older Hispanic Americans about one and a half times as likely, as older White Americans to have Alzheimer's or another dementia (Alzheimer's Association). Yet these groups have often been underrepresented in Alzheimer's trials, which makes it harder to know how new treatments work for the people most affected. Our Alzheimer's disease page lists studies recruiting now.
What rules and policies say
Several US policies address who takes part in research. The NIH Revitalization Act of 1993 requires NIH-funded clinical research to include women and members of racial and ethnic minority groups, and since 2019, the NIH's Inclusion Across the Lifespan policy has required funded studies to include people of all ages unless there is a scientific or ethical reason not to (NIH). In 2020, the FDA issued guidance encouraging sponsors to broaden eligibility criteria, make enrollment easier, and design trials that more people can join (FDA).
The Food and Drug Omnibus Reform Act of 2022 went further, requiring sponsors of phase 3 and other pivotal studies to submit Diversity Action Plans with enrollment goals by age, sex, race, and ethnicity. That requirement only takes effect 180 days after the FDA publishes final guidance. The FDA released draft guidance in June 2024; the draft was briefly removed from the agency's website in early 2025 and later restored, and as of mid-2026 the final guidance had not been published. Many sponsors already set enrollment goals voluntarily.
What researchers can do to improve diversity
Much of the solution lies in study design and logistics. Researchers can keep eligibility criteria as broad as safety allows, choose study sites closer to the communities affected by a condition, and add remote or decentralized elements such as home visits or video check-ins to reduce travel. Reimbursing costs such as transport and parking, offering materials in several languages, working with community organizations and local doctors, and responding promptly to people who express interest all make a difference. Our guide explains how eligibility criteria work and how compensation and reimbursement work.
What this means for you
If you have thought about taking part in research but assumed studies were not looking for someone like you, the opposite is often true. Many studies actively seek participants of different ages and backgrounds, and older adults, people with other health conditions, and people from underrepresented communities are especially needed. Taking part is always voluntary, the study is explained to you before you agree, and you can leave at any time. Our guides explain what to know before participating and how to volunteer for a clinical trial, and many studies also need healthy volunteers.
Frequently asked questions
Why is diversity important in clinical trials?
Because medicines can work differently depending on age, sex, genetics, and other health conditions. Testing them in a wide range of people helps make sure they are safe and effective for everyone who will use them.
Are clinical trials more diverse now than in the past?
In some ways. Women and older adults are included more often than decades ago, but a 2025 analysis of pivotal trials from 2017 to 2023 found that only 6% enrolled participants in proportions close to the US population, and the share of Black and Hispanic participants decreased over that period.
Does the FDA require diversity in clinical trials?
A 2022 law requires sponsors of pivotal studies to submit Diversity Action Plans, but the requirement only takes effect after the FDA publishes final guidance, which had not happened as of mid-2026. The FDA has encouraged broader participation through earlier guidance.
Why are some groups less likely to take part in clinical trials?
Common reasons include never being invited, distance to study sites, time and cost, strict eligibility criteria, language barriers, and mistrust rooted in past research abuses.
How can I join a clinical trial?
You can search for studies by condition and location on AllClinicalTrials.com and apply in about 5 minutes. The study team then explains the study and goes through informed consent with you before any screening tests.
